Efficacy of silodosin plus fesoterodine versus silodosin plus mirabegron in patients with benign prostatic enlargement complicated by overactive bladder

Trial Profile

Efficacy of silodosin plus fesoterodine versus silodosin plus mirabegron in patients with benign prostatic enlargement complicated by overactive bladder

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Silodosin (Primary) ; Fesoterodine; Mirabegron
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 New trial record
    • 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top